Skip to content
AnalystLens

Halozyme TherapeuticsHALO

Legal name
Halozyme Therapeutics, Inc.
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq

Stock Price $HALO

You are here#59 of 59 in Healthcare by market cap

Filing record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’18Mar ’18
  2. FY2019 annual report10-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  1. $1.40B
YoY changeLargest recent move+115.8%in FY17Latest +37.6%

1 older move runs past ±150% (largest +311.7%); point at, tap or drag across the bars to read one.

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →

Halozyme Therapeutics Financial Overview 2021–2025

Updated Nov 6, 2026

Halozyme grew revenue 38% to $1,396.6 million in FY2025, yet net income fell to $316.9 milliona from $444.1 million. The gap came from deal charges, not weaker demand. The thesis: a royalty engine is compounding fast, while acquisitions and buybacks have traded a cash cushion for leverage. Royalties jumped 52% to $867.8 million, led by DARZALEX SC, VYVGART Hytrulo and Phesgo.

Zoom out and the scale shift is stark. Revenue grew from $443.3 million in FY2021 to $1,396.6 millionb in FY2025, more than tripling. The FY2025 earnings dip had specific causes. Operating income slipped to $469.0 million from $551.5 million after $284.9 million of acquired in-process R&D from the Surf Bio deal and a $48.7 million intangible impairment. Diluted EPS landed at $2.56, versus $3.43 in FY2024.

The balance sheet is where the risk sits. Cash and marketable securities fell to $142.8 millionc at year-end, while long-term debt reached $2,142.6 million after the $750.0 million Elektrofi-related and Surf Bio acquisitions and $1.5 billion of new convertible notes. Stockholders' equity shrank to $48.8 million from $363.8 million, with $342.4 million of repurchases in FY2025. The market still paid up: at the close of FY2025, shares traded at $67.30, or 26.3x earnings, for a $7.9 billion market cap.

Recent Developments (Q2 and Q3 2026)

Halozyme accelerated its momentum through Q2 2026 and Q3 2026, driven by surging partner demand for ENHANZE-enabled therapies. Total revenue reached $481.0 milliond in Q2 2026 and grew 39% year-over-year to $493.0 million in Q3 2026, while net income expanded to $229.0 million and $247.0 million across the respective periods. Management raised full-year guidance twice, bolstered by five new partnerships secured through July and a favorable Dutch patent ruling against Merck. To support ongoing capital allocation, the company issued $1.5 billion of convertible notes in September, lifting total cash and marketable securities to $1.07 billion by the close of Q3 2026.

The bull case centers on expanding royalty streams and robust clinical advancement, while the bear case highlights potential intangible asset risks if partner-specific Hypercon targets are returned. Shares trade at 48.0xe earnings as of the Q3 2026 filing, reflecting a rich multiple for the scaling royalty engine.

What to watch: Partner milestone decisions on Hypercon targets by February 2027; European market impact from the Merck patent injunction.

Recent SEC Filings

  1. 8-KHalozyme Therapeutics 8-K Report, Financial Results (Nov 5, 2026)Halozyme Therapeutics reported a strong third quarter of 2026, with total revenue growing 39% year-over-year to $493 million and royalty revenue increasing by 44% to $341 million. This robust performance has prompted the company to raise its full-year 2026 financial guidance across key metrics including total revenue, royalty revenue, Adjusted EBITDA, and Non-GAAP Diluted EPS. The company also highlighted significant progress in its ENHANZE® collaboration agreements, expanding partnerships with three current collaborators and advancing three ENHANZE® programs into Phase 1 clinical development. A notable legal victory was also achieved, with a Dutch patent court ruling in favor of Halozyme in an infringement case against Merck concerning its Keytruda Qlex product, leading to an injunction in several European markets. The company further strengthened its financial position by completing a $1.5 billion convertible notes offering.
  2. 8-KHalozyme Therapeutics 8-K Report, Executive Changes (Sep 30, 2026)Halozyme Therapeutics, Inc. filed this Form 8-K to report under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) that James Daly was elected to the Board of Directors on September 28, 2026. Mr. Daly was elected to the class of directors whose terms end at the Company's annual meeting of stockholders in 2029, and was not initially assigned to any Board committee. As a non-employee director, Mr. Daly will receive compensation under the Company's director compensation program, as revised from time to time. The filing states that current components of that program consist of cash retainers for Board and committee service, restricted stock and stock option awards, and that these components were described in the proxy statement for the 2026 Annual Meeting of Stockholders held on May 5, 2026. The filing states there are no arrangements or understandings under which Mr. Daly was elected as a director, and no related person transactions between the Company and Mr. Daly.
  3. 8-KHalozyme Therapeutics 8-K Report, Material Agreement (Sep 22, 2026)On September 22, 2026, Halozyme Therapeutics, Inc. completed the sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including $200.0 million issued under the initial purchasers' option. The Company received net proceeds of approximately $1,471.1 million after discounts, commissions and estimated offering expenses. The notes were sold under Section 4(a)(2) of the Securities Act and Rule 144A to qualified institutional buyers, and are unsecured obligations that rank senior to subordinated indebtedness and equally with existing unsubordinated liabilities. Interest is payable semi-annually on April 1 and October 1, beginning April 1, 2027. The Company used approximately $187.5 million of the proceeds to fund capped call transactions, which are intended to reduce potential dilution on conversion, subject to a cap price of approximately $208.39 per share. It also expects to use part of the proceeds to repurchase $151.7 million of its 0.25% convertible notes due 2027 and $220.0 million of its 1.00% convertible notes due 2028, for total repurchase costs of approximately $217.0 million and $435.5 million, respectively, including accrued interest. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases. The notes have an initial conversion rate of 7.1509 shares per $1,000 principal amount, equivalent to a conversion price of approximately $139.84 per share, and the Company may settle conversions in cash, shares, or a combination at its election. Conversion is permitted under specified conditions, including a share price test of 130% of the conversion price and at any time from April 1, 2033 until shortly before maturity. The notes are redeemable at the Company's option on or after October 7, 2030 subject to a share price condition, and a cleanup redemption is available if less than $100.0 million remains outstanding. Holders may require repurchase at par plus accrued interest upon a fundamental change.
  4. 8-KHalozyme Therapeutics 8-K Report, Corporate Update (Sep 18, 2026)On September 17, 2026, Halozyme Therapeutics, Inc. priced an upsized private offering of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due October 1, 2033. The offering was increased from the previously announced $1.05 billion, and the initial purchasers received a 13-day option to buy up to an additional $200 million of notes. The notes are senior, unsecured obligations, and the company expects to close the offering on September 22, 2026. The company expects net proceeds of approximately $1.275 billion, or approximately $1.471 billion if the option is exercised in full. The initial conversion rate is 7.1509 shares per $1,000 principal amount, equal to an initial conversion price of approximately $139.84 per share, a conversion premium of approximately 27.5% above the $109.68 closing price on September 17, 2026. The company will settle conversions in cash and, if applicable, shares, at its election. The company plans to use approximately $162.5 million of the net proceeds to fund capped call transactions, with an initial cap price of approximately $208.39 per share, a premium of approximately 90.0% above the September 17, 2026 last reported sale price. Concurrently, the company intends to repurchase $151.7 million principal amount of its 0.25% convertible senior notes due 2027 for a total cost of approximately $217.0 million, including accrued interest, and $220.0 million principal amount of its 1.00% convertible senior notes due 2028 for a total cost of approximately $435.5 million, including accrued interest. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and future note repurchases or repayment. The filing notes that the note repurchases and related hedging activity by counterparties and holders could affect the market price of the common stock and the notes.
  5. 8-KHalozyme Therapeutics 8-K Report, Corporate Update (Sep 16, 2026)Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced on September 16, 2026 that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033. The company also expects to grant the initial purchasers a 13-day option to buy up to an additional $150 million of the notes. The notes are being offered only to qualified institutional buyers under Rule 144A, and the filing states they will be senior, unsecured obligations that accrue interest payable semi-annually and mature on October 1, 2033. Conversions will be settled in cash and, if applicable, shares of common stock, at the company's election. The initial conversion rate, interest rate and other terms will be set at pricing. Halozyme states it expects to use a portion of the net proceeds to fund the cost of capped call transactions and to repurchase portions of its outstanding 0.25% convertible senior notes due 2027 and 1.00% convertible senior notes due 2028 through privately negotiated transactions. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases or repayment of the notes at maturity or upon early optional redemption. The filing notes that the note repurchases and related hedging activity by counterparties could affect the market price of the common stock and the notes, and the capped calls are generally expected to reduce potential dilution from conversions. The filing is a notice of a proposed offering and does not state final pricing, size of the option exercise or closing results. The accompanying press release also describes the company's ENHANZE drug delivery technology, Hypercon and Surf Bio hyperconcentration technologies, and its Hylenex and XYOSTED commercial products.
View all 8-K filings →